
Sentinal4D is an AI-powered drug discovery company focused on oncological and other severe diseases. They leverage a biology-first, holistic approach utilizing AI-powered 3D cell imaging and deep learning for phenotypic-based drug discovery. This unique integration of technology and biological expertise provides deeper insights into cellular biology, aiming to accelerate the development of personalized therapeutics from the lab to the clinic. Their scientific team has extensive experience in cell biology research and the cell omics space.

Sentinal4D is an AI-powered drug discovery company focused on oncological and other severe diseases. They leverage a biology-first, holistic approach utilizing AI-powered 3D cell imaging and deep learning for phenotypic-based drug discovery. This unique integration of technology and biological expertise provides deeper insights into cellular biology, aiming to accelerate the development of personalized therapeutics from the lab to the clinic. Their scientific team has extensive experience in cell biology research and the cell omics space.
Headquarters: London, United Kingdom
Founded: 2024 (spin-out from The Institute of Cancer Research, ICR)
Focus: AI-powered 3D/4D cellular analysis for drug discovery and single-cell tumor diagnostics
Products: SentiCORE platform with models/pipelines such as FORM and MorphoSense
Funding (early-stage): Dec 2024 round with Twin Path Ventures and Arben Ventures; amount undisclosed
Founders / Leadership (reported): Chris Bakal; Matt De Vries; reported co-founder Dr. Georgia Mitsi
Phenotypic-based drug discovery and single-cell morphological diagnostics in oncology
2024
Biotechnology
Reported investors for the Dec 2024 round include Twin Path Ventures, Arben Ventures, James Thomas, and Catherine Thomas; amount undisclosed.
“Backed by early-stage investors including Twin Path Ventures and Arben Ventures plus angel investors”